Source:http://linkedlifedata.com/resource/pubmed/id/16369751
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
2005-12-21
|
pubmed:abstractText |
Cardiotoxicity is a rare complication occurring during 5-fluorouracil (5-FU) treatment for malignancies. We herein report the case of a 70-year-old man with 5-FU-induced cardiotoxicity, in whom a high serum level of alpha-fluoro-beta-alanine (FBAL) was observed. The patient, who had unresectable colon cancer metastases to the liver and lung, was referred to us for chemotherapy from an affiliated hospital; he had no cardiac history. After admission, the patient received a continuous intravenous infusion of 5-FU (1000 mg/day), during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng/ml. Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5-FU. As the precordial pain in this patient was considered to have been due to 5-FU-induced cardiotoxicity, the administration of 5-FU was abandoned. Instead, oral administration of S-1 (a derivative of 5-FU), at 200 mg/day twice a week, was instituted, because S-1 has a strong inhibitory effect on dihydropyrimidine dehydrogenase, which catalyzes the degradative of 5-FU into FBAL. The serum FBAL concentration subsequently decreased to 352 ng/ml, the same as the value measured on the first day of S-1 administration. Thereafter, no cardiac symptoms were observed. The patient achieved a partial response 6 months after the initiation of the S-1 treatment. The experience of this case, together with a review of the literature, suggests that FBAL is related to 5-FU-induced cardiotoxicity. S-1 may be administered safely to patients with 5-FU-induced cardiotoxicity.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur,
http://linkedlifedata.com/resource/pubmed/chemical/alpha-fluoro-beta-alanine,
http://linkedlifedata.com/resource/pubmed/chemical/beta-Alanine
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
1341-9625
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
441-3
|
pubmed:meshHeading |
pubmed-meshheading:16369751-Aged,
pubmed-meshheading:16369751-Antimetabolites, Antineoplastic,
pubmed-meshheading:16369751-Cardiovascular Diseases,
pubmed-meshheading:16369751-Colonic Neoplasms,
pubmed-meshheading:16369751-Drug Combinations,
pubmed-meshheading:16369751-Electrocardiography,
pubmed-meshheading:16369751-Fluorouracil,
pubmed-meshheading:16369751-Heart,
pubmed-meshheading:16369751-Humans,
pubmed-meshheading:16369751-Liver Neoplasms,
pubmed-meshheading:16369751-Lung Neoplasms,
pubmed-meshheading:16369751-Male,
pubmed-meshheading:16369751-Oxonic Acid,
pubmed-meshheading:16369751-Tegafur,
pubmed-meshheading:16369751-beta-Alanine
|
pubmed:year |
2005
|
pubmed:articleTitle |
5-Fluorouracil cardiotoxicity induced by alpha-fluoro-beta-alanine.
|
pubmed:affiliation |
Department of Surgery, Niitsu Medical Center Hospital, Niigata, Japan.
|
pubmed:publicationType |
Journal Article,
Case Reports
|